Eversheds reacts to high number of medicines being blocked from UK market
In response to calls from the pharmaceutical industry that the number of medicines being blocked from the UK market by the National Institute for Health and Care Excellence (NICE) is too high, Simon Crossley, partner and head of life sciences at Eversheds, has commented.
Crossley said that with UK government austerity measures showing no signs of fading, there is an ‘obvious tension’ between the pharmaceutical industry and NICE.
He said: ‘While the industry understandably wants to access markets for new products, NICE effectively creates a further hurdle once clinical trials have been successful, to ensure that new medicines, made available through public funds, are assessed to ensure treatments are cost effective.
‘NICE decisions are being regularly challenged by the industry in private, and it’s telling that a group of companies has now gone public with its concerns, forcing NICE to justify its stance.’
News from Eversheds
News from The Lawyer
Briefings from Eversheds
Rather than a single new body to take on its role, the OFT’s functions have been spread between a number of different bodies, some old and some new.
As it moves into its second year as the FCA, the FCA has recently published its Business Plan for 2014–15 and its second annual Risk Outlook.
Analysis from The Lawyer
A new breed of lawyer is smoothing the path for companies entering emerging or unstable jurisdictions
‘Exotic’ investors and opportunities for legal work beyond M&A feature in The Lawyer’s high-level roundtable debate on south-east Europe